Identification of key research needs for topical therapy treatment of psoriasis - a consensus paper by the International Psoriasis Council

In this age of expanding choices of therapy for psoriasis, topical therapies still play an important part in the management of patients. There are many knowledge gaps in topical therapy for psoriasis with regard to efficacy and safety as well as various combinations including topical therapy with ph...

Full description

Saved in:
Bibliographic Details
Published inJournal of the European Academy of Dermatology and Venereology Vol. 30; no. 7; pp. 1115 - 1119
Main Authors Wu, J.J., Lynde, C.W., Kleyn, C.E., Iversen, L., van der Walt, J.M, Carvalho, A., Kirby, B., Bissonnette, R.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.07.2016
Subjects
Administration, Topical
Consensus
Dermatologic Agents - therapeutic use
Humans
Phototherapy
Psoriasis - drug therapy
Psoriasis - therapy
Online AccessGet full text

Cover

More Information
Summary:In this age of expanding choices of therapy for psoriasis, topical therapies still play an important part in the management of patients. There are many knowledge gaps in topical therapy for psoriasis with regard to efficacy and safety as well as various combinations including topical therapy with phototherapy or with systemic agents. Councillors of the International Psoriasis Council comprised a topical therapy working group to describe these gaps in order to help direct future research endeavours. Herein, we present the results of this analysis, discuss topical agents in clinical development and the attributes of the ideal topical treatment for psoriasis.
Bibliography:ArticleID:JDV13614
istex:8AE1EB930D73F881EA4FF33FB8FD9B59E9D8476A
ark:/67375/WNG-5K5QB0G8-X
Funding Sources
None.
Dr. Wu received research funding from AbbVie, Amgen, Coherus Biosciences, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Regeneron, and Sandoz; he is a consultant for AbbVie, Amgen, Celgene, DUSA Pharmaceuticals, Eli Lilly, and Pfizer. Dr. Lynde received honoraria or research from Allergan, Amgen, AbbVie, Astellas, Celgene, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer Merck, Stiefel/GSK and Novartis. Dr. Kleyn received research funding from Pfizer, Janssen, Johnson & Johnson and honoraria from AbbVie, Amgen, Galderma, Janssen, Leo Pharma, and Stiefel/GSK. Professor Iversen has been a speaker for MSD, Pfizer, Abbott, Almirall, Janssen Cilag and LEO Pharma. Consulting or serving on expert/advisory boards with Pfizer, Abbott, Almirall, Janssen Cilag, Novartis, LEO Pharma and MSD; and receiving research and educational grant from Pfizer, AbbVie, Novartis and MSD. Dr. Carvalho has received grants/research support from Galderma and Janssen. He has served as a consultant/speaker bureau member for AbbVie, Glenmark, Janssen, LEO‐Pharma, and Pfizer and as an advisory board member for AbbVie, Janssen, LEO‐Pharma, and Pfizer. Professor Kirby Dr. Kirby received research funding from AbbVie, Pfizer, Merck‐Sharpe‐Dolme and Novartis. He is a consultant for AbbVie, Pfizer, Janssen, Celgene and Roche. Dr. Bissonnette received honoraria or research funding from Allergan, Amgen, AbbVie, Astellas, Celgene, Eli‐Lilly, Galderma, Kineta, Leo Pharma, Stiefel/GSK, Janssen, Leo Pharma, Pfizer, Merck and Novartis.
Conflict of interest
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.13614